It has previously been shown that longterm administration of insulin-like growth factor-I (IGF-I) or the analogue Long R3 IGF-I (LR3IGF-I) selectively stimulate growth of the gastrointestinal tract in gut resected, dexamethasone treated, and normal rats. In this study, the short-term effects of IGF-I administration on intestinal proliferation have been investigated. Female rats (110 g, five-six/group) were infused for three days with 2.5 mg/kg/day ofeither IGF-I or LR3IGF-I and compared with vehicle treated or untreated control rats. LR3IGF-I but not IGF-I increased body weight and wet tissue weight of the small and large intestine (+20%), compared with controls. Tissue weight responses were independent of food intake and were reflected in the histology ofthe tissue. In LR3IGF-I treated animals, duodenal and ileal crypts length were increased by 13 and 22%, respectively, associated with an increase in crypt cell number. No such histological changes were seen in IGF-I treated rats. Tritiated thymidine labelling indices were significantly increased after administration of either IGF-I or LR3IGF-I (up to 14%) in both the duodenum and ileum. In IGF-I treated rats, increased nuclear labelling was not associated with an increase in the crypt compartment. In contrast, LR3IGF-I induced proportional increments in thymidine labelling and crypt size, suggesting that LR3IGF-I is not only more potent than the native peptide but also induced proliferative events more rapidly. In the colon, the thymidine labelling index was low, however, a non-significant increase in the number of cells labelled with thymidine was seen. These results suggest that within a three day treatment period intestinal mitogenesis is more advanced in animals treated with LR3IGF-I. The differences in proliferative response between the two peptides may be accounted for by variations in pharmacokinetics, clearance rates, and interactions with circulating and tissue specific binding proteins. (Gut 1995; 37: 630-638) 
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Insulin-like growth factors (IGF-I and IGF-II) are multifunctional polypeptides that possess the ability to exert insulin-like metabolic activity and regulate cell proliferation and differentiation in a variety of cell types and tissues. IGF-I mediates growth hormone dependent growth and stimulates somatic growth and that of visceral organs including the kidneys, thymus, adrenals, and the spleen. In the circulation, IGFs are bound to specific IGF binding proteins, which function as modulators of IGF action. They interact with their target tissues by membrane bound receptors to act in an autocrine, paracrine or endocrine manner, or all three. 1 IGFs are ubiquitously distributed and have been detected in tissue extracts as well as body fluids. IGF-I immunoreactivity has been shown in the human fetal stomach2 and in fetal rat intestine.3 In neonatal pigs, growth and maturation of the intestinal mucosa coincides with an increase in IGF-I immunoreactivity.4 Furthermore, IGF-I immunoreactivity has also been shown in saliva, gastric, pancreatic, and extrapancreatic excretions and in jejunal chyme.5
Several studies in animal models of gastrointestinal adaptation have shown that administration of IGF-I peptides selectively stimulate growth of the gastrointestinal mucosa.68 More recently, we have shown that IGF-I peptides also play an important part in gastrointestinal growth and function in normal adult rats.9 In that study we gave increasing doses of IGF-I or LR3IGF-I, a potent analogue with an N-terminal extension showing reduced binding affinity to IGF-binding proteins as well as the type 1 receptor,10 for 14 days to normal, female rats. After the 14 days of treatment with either IGF-I or LR3IGF-I, body weight gain and gastrointestinal weights were significantly increased. The LR3IGF-I was severalfold more potent than the native IGF-I in all responses. Furthermore, wet tissue weights were increased in a dose dependent manner and the proximal small intestine was identified as the most responsive region. Detailed histological analyses showed that IGF-I peptide administration stimulated the growth of the proliferative compartment (crypt) and the functional compartment (villi) , so that at the end of the 14 day treatment period crypt depth and villus height were increased by up to 30% above control values. More importantly, however, IGF-I peptide administration induced a pro-enterocytes as shown by immunohistochemical detection of cells positive for proliferative cell nuclear antigen (PCNA). The proportionality between the proliferative and maturation compartment of the crypt as well as between crypts and the villi was maintained.9 These findings have led to the conclusion that administration of either IGF-I or LR3IGF-I peptide for a prolonged period stimulate mucosal growth, resulting in a new steady state between cell loss and cell production.
This study was undertaken to identify the early proliferative responses of the intestinal epithelium that led to this new steady state after IGF-I or LR3IGF-I administration. IGF-I and LR3IGF-I were compared to determine if the two peptides differed in their potency to evoke proliferative responses of the intestinal epithelium during this early period. Furthermore, we investigated if the proliferative responses were similar in different regions of the intestine. In review of the results from the aforementioned study, a short-term infusion protocol was used. The age and body weights of the rats as well as the peptide dose and infusion protocol have been replicated so that direct comparisons could be made between the two studies.
Methods RECOMBINANT IGF-I PEPTIDES
Recombinant human IGF-I and the recombinant analogue LR3IGF-I was provided by GroPep Experimental protocol IGF-I peptides were infused subcutaneously for a three day period. All animals were acclimatised to the metabolism cages for a three day period, followed by a four day pretreatment period. During the pretreatment period and the three days of peptide infusion, daily measurements of body weight, food, and fluid intake as well as urinary and faecal output were taken at precisely 24 hour intervals. Between 0900 and 1200 hours on the morning after the pretreatment period, the rats were anaesthetised with 0.04 ml/kg Brietal for osmotic mini-pump (Alzet, Model 1 003D, Alza, Palo, CA, USA) implantation within the subcutaneous scapular region. The pumps were filled with either IGF-I or LR3IGF-I or contained the vehicle alone (0.1 M acetic acid). Each rat received 2-5 mg/kg/day of either IGF-I or LR3IGF-I, thus at a mean pumping rate of 0 99 ,lp/h, each rat received 278 ,ug/day for a three day period. There were six rats in each of the vehicle, IGF-I, and LR3IGF-I treated groups and a control group (n= 5), receiving no treatment or pump was also included. The study was divided into two animal trials. The first trial contained three rats from each of the two peptide treatment groups, three vehicle treated rats, and three untreated control animals. The second trial contained three rats from each of the peptide treated and vehicle treated groups and two untreated control animals. The trials were staggered by one day. The pumps were not primed before implantation, so that in accordance with the manufacturer's instructions, the full pumping rate would be reached approximately four hours after insertion of the pumps between 1300-1600 hours. No special postoperative care of the animals was required.
During the three days of peptide infusion, daily measurements of body weights and metabolic collections were continued. At the end of the three day treatment period between 1300 and 1600 hours, each animal was injected with a single intraperitoneal injection of 0 5 ,uCi/g body weight of tritiated thymidine (Amersham International, Buckinghamshire, England, specific activity 25 The dose of tritiated thymidine used in this study produced clear labelling of S-phase nuclei, showing numerous black grains deposited over the nuclei and a negligible background. A minimum of six grains per nuclei was used to define positively labelled cells. Preliminary analyses determined that the slides had to be exposed for at least 10 days to obtain adequate signal of the isotope. Accordingly, all analyses were carried out on sections exposed for 10 days. Proliferative parameters were assessed in 30 crypts from each animal in the duodenum, ileum, and colon. Analyses were confined to crypts where the entire length could be completely visualised and which contained a single layer of epithelial cells only. In each crypt, a single column (right hand column) along the longitudinal axis of the crypt was assessed and the total number of cells and the number and position of tritiated thymidine labelled cells was recorded. For each of the intestinal regions, the labelling index was calculated as the ratio of labelled cells to total cell number for each crypt column. In addition, the circumferential cell count (crypt row count), measured as the number of epithelial cells around the circumference at the crypt:villus junction was measured in the duodenum and ileum in serial cut sections from tangentially embedded material. The product of the crypt column count and the crypt row count was used to estimate the total crypt cell population in all small intestinal regions.
For each animal, thymidine labelling index distribution profiles were established for the duodenum and the ileum. From these curves, the cell position within the crypt at which maximal thymidine labelling occurs and the cell position of half maximum thymidine labelling was identified. The maturation compartment of the crypt in which epithelial cells have lost their proliferate capabilities and acquire their mature, functional properties was identified from these curves as the region above the last labelled cells within the crypt. To determine if IGF-I peptides increase thymidine incorporation into enterocytes in the lower and mid-crypt region, the cumulative number of cells labelled with tritiated thymidine up to cell position 19 was calculated. The crypt growth fraction, which identifies the proportion of proliferating cells within the crypt, was calculated for each animal from the thymidine labelling distribution profiles of 30 perfectly orientated crypts by dividing the cell position at which half maximum labelling occurred by the total number of cells per cell column. Tables and Figures are weight gain to food consumption for the three day treatment period was highly significant in the LR3IGF-I treated group (p<0.0001) when compared with either vehicle, control or IGF-I treated animals (Fig 1) . To determine if the accelerated weight gain in the LR3IGF-I treated animals could be attributed to fluid retention, the fluid balance (fluid intake/24 hours minus fluid output/24 hours) was estimated for all animals. Although fluid intake was highly variable throughout the three day treatment period in all groups, no statistically significant difference was detected in either fluid intake or urinary output over the experimental period, arguing against fluid retention as a possible mechanism for the extra weight gain seen in LR3IGF-I treated rats (results not shown). To examine the degree to which body weight gain and the fluid balance correlate after IGF-I peptide treatment, productmoment correlation coefficients were calculated for the combined data. No statistical significant correlation was found between body weight gain and the fluid balance during the three day treatment period in either treated or untreated rats (robtained=0.27, rcritical=0A42 at p<005).
Statistical analyses All values in
Gastrointestinal weight in the animals fitted with the vehicle pump was similar to the gut weight of untreated control rats, showing that implantation of the pumps had no effect on gastrointestinal tissue growth. Comparison between the vehicle group and the animals treated with 2.5 mg/kg/day of LR3IGF-I showed, however, that the increased body weight gain in the LR3IGF-I group was reflected in the wet tissue weights of their gastrointestinal tissues. Total gut weight, small and large intestinal weight were increased by 19%, 22%, and 21% respectively compared with vehicle treated animals (Fig 2 (A) , (C), and (D)), while stomach weight increased by 12% after treatment with LR3IGF-I (Fig 2  (E) ). Selective action of LR3IGF-I on the intestinal tissues was evident when corrections for body weight gain were made, so that fractional gut weight (total gut weight/kg body weight) was significantly increased in LR3IGF-I treated animals (56-6 (1-4), p<O0O1) compared with either IGF-I (48.5 (1.3)) or vehicle treated control animals (503 (1. 1)) , Fig 2 (B) . The increase in gastrointestinal tissue weight in LR3IGF-I treated animals contrasts considerably with the results obtained for IGF-I treated animals, so that infusion of 2.5 mg/kg/day of recombinant IGF-I did not affect body weight gain or gastrointestinal tissue weights (Table I and Fig 2 (A-E) ). Increases in intestinal length were not seen in any of the animals treated for three days with the IGF-I peptides (results not shown).
We have previously shown that longterm administration of 2-5 mg/kg/day of IGF-I peptides to normal female rats selectively stimulated the growth of intestinal mucosa, so the main focus here was to assess the mitogenicity of IGF peptides during the initial period of peptide administration. In this study, administration of LR3IGF-I for only three days resulted in a statistically significant increase (Table   II) .
To further assess the mitogenic properties of the IGF-I peptides on the intestinal epithelium, we constructed thymidine labelling distribution profiles of the duodenum and ileum for each animal. In the duodenum of control or vehicle treated animals a total of 29-30% of the crypt cells were labelled with the isotope (crypt labelling index), Table III (Table III and (Fig 3 (A) and (B) ). Thus the maturation compartment of the crypt was identified from cell position 29 upwards. The IL crypt growth fraction for the vehicle and untreated control rats was calculated at approximately 60%. In the duodenum of the LR3IGF-I treated animals, the crypt cell labelling index was significantly increased (32.7%) compared with the control groups (29-30%), Table III . As for the control and vehicle groups, low proliferative indices were evident in the first few cell positions, however, increased crypt cell labelling was reflected in an increased maximum labelling, calculated at 66%, at cell positions [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] (Table III and Fig 3 (D) ). Furthermore, the number of thymidine labelled cells up to cell position 19 was also significantly greater in LR3IGF-I treated rats compared with either vehicle or untreated control rats (Table III) . After cell position 16 (8) 203 (7) 192 (5) 231 (4) (11) 588 (16) 723 (26) proportion to the total number of crypt cells and hence, the crypt growth fraction remained at approximately 60%, Table III and Fig 3 (D) . The labelling distribution profiles in IGF-I treated rats also showed an increase in the overall crypt cell labelling index, which was virtually identical to that in LR3IGF-I treated rats (Table III) . In this group, the number of cells labelled with tritiated thymidine in basal and mid-crypt enterocytes (up to cell position 19) was also significantly increased (Table III) , so that maximum thymidine labelling (66.7%) was reached within cell positions 5-16. Consequently, thymidine labelling in the lower and mid-crypt region in IGF-I treated animals was increased by 9% and 14% compared with vehicle treated or control rats, respectively. However, this failed to achieve statistical significance (p<0 067) (Table III and Fig 3 (C) ).
In contrast with the LR3IGF-I group, nuclear labelling declined more rapidly after cell position 16 (similar to the vehicle and control group) so that half maximum labelling was reached at cell position 20 in IGF-I treated rats, which was virtually identical to control values (Table III and Fig 3 (C) ). As the total number of cells per crypt column was not changed in this group, the overall crypt growth fraction was maintained at 58% and comparable with the crypt growth fraction of the control groups (Table III) . Thus, the mechanism by which IGF-I induced epithelial proliferation in this short-term administration protocol differed from that of the LR3IGF-I group. Despite the considerable increase in the proliferative pool, short-term IGF-I administration did not increase the cellularity of the crypt. Increased crypt labelling was therefore achieved by increasing the proportion of proliferative cells in lower and mid-crypt positions as shown by the increase in maximal labelling rather than a recruitment of proliferative cells in higher cell positions, as seen in the LR3IGF-I group.
In the ileum, the overall crypt labelling index was lower than in the duodenum (Table III) . This was reflected by lower thymidine labelling indices in the basal positions as well as a lower maximal labelling. On the other hand, the position of half maximum labelling was similar in the two intestinal regions (Table III) . As for the duodenum, LR3IGF-I treated animals showed an increased number of proliferative cells in higher cell positions (as shown by the upward shift in the 1/2 maximum labelling), while IGF-I treatment seemed to increase the proportion of proliferative enterocytes in the mid-crypt cell positions (Table III) , reaching a maximum thymidine labelling index of 60% compared with 54-57%/o in the control groups (Table III) . This led to a non-significant (p<0 08) increase in the crypt growth fraction in this group (Table III) .
Finally, the mitogenic response of the colonic mucosa to IGF-I peptides was assessed in tissue segments from the proximal colon. Although, similar changes in wet tissue weight in LR3IGF-I treated rats were seen for the small and large intestine, thymidine labelling indices were not increased by IGF-I peptides (Table IV) . Nevertheless, in LR3IGF-I treated rats, an average of 3-7 cells per crypt were labelled compared with 2.9 cells/crypt in vehicle or untreated control rats (Table IV) . Although, statistical significance was not reached, it is possible that IGF-I peptides effects in the colon have been disguised by the inherent low proliferative activity of the colon. In this study, thymidine labelling indices were 11-13% for all groups with no statistical difference between treatment groups. The site at which histological samples for the colon were taken show a great deal of heterogeneity in crypt morphology. For example, the proximal TABLE III Proliferative parameters in the duodenum and ileum ofrats treatedfor three days with 2.5 mg/kg/day ofIGF-I or LR3IGF-I as compared with vehicle and untreated control rats colon contains mucosal rugae and the crypts at the apex of mucosal folds are longer than the crypts at the base of the crypts. Consequently, the colonic crypt cell population could not be established because serial cut sections of longitudinal embedded material does not provide a uniform display of crypts suitable for circumferential crypt row counts in this region. Because of the low proliferative activity in the colon, labelling distribution curves were also not established for this region.
Discussion
We have previously shown that longterm infusion of IGF-I and in particular LR3IGF-I intestine.14 The tritiated thymidine uptake by canine fundic epithelial cells is also stimulated by IGF-I administration although EGF and insulin are also able to elicit a mitogenic response in these cells, much higher concentration of these growth factors are needed to achieve an equivalent effect. '5 In this study, administration of IGF-I and LR3IGF-I for a three day period stimulated the thymidine incorporation into crypt epithelial cells in vivo, supporting that in the adult rat, IGF-I peptides are important intestinal mitogens. From the thymidine labelling distribution profiles in the control groups, it was evident that maximal thymidine incorporation was greatest in the mid-crypt region (cell position 5-16), which represents the zone of greatest cell production. As shown by Wright,'6 this is the 'proliferative compartment proper' and the labelling index obtained in this region in our study compares well to the theoretical labelling index of 60%. After treatment with IGF-I, an increase in the number of proliferative cells in lower and mid-crypt cells positions showed that more cells in this region of the crypt had entered the cell cycle, leading to the observed increase in the thymidine labelling index in this group. In addition, the maximum labelling was also increased, which shows that more cells in the proliferative compartment proper were cycling. The most probable mechanism by which such a rapid increase in proliferative activity may have been achieved is a reduction in the cell cycle in enterocytes in basal cell positions. Cell The most interesting finding of this study was the fact that although both IGF peptides significantly increased the thymidine incorporation into the crypt enterocytes, increased proliferative activity associated with an increase in the size of the crypt compartment was only seen in the LR3IGF-I treated animals.
Although we cannot exclude the possibility that the mechanism by which the two peptides induce proliferative events differs, it is highly likely that the proliferative responses seen in animals treated with LR3IGF-I represent a more 'advanced' stage of intestinal proliferation compared with the IGF-I treated rats. This is supported by the fact that in rats treated for 14 days with either IGF-I or LR3IGF-I a considerable increase in size of the crypt compartment was seen, for both groups. This suggests that although both peptides initiate increased thymidine incorporation after three days, in LR3IGF-I treated animals this has been already translated into an increase in crypt size, which in IGF-I treated animals occurs some time later. Thus, the proliferative effect seen in the rats infused with IGF-I should be detectable after administration of LR3IGF-I for only one or two days.
Another point of interest was the finding that administration of LR3IGF-I resulted in a greater proportion of cycling cells in upper crypt cell positions, showing that migrating enterocytes had retained their proliferative capacities and had not entered the maturation compartment of the crypt. Moreover, it seems that in LR3IGF-I treated animals the proliferative response was approaching the new steady state equilibrium between cell production and cell loss that was seen in the rats treated for 14 days with IGF-I peptides. This may have been achieved by a change in enterocyte transit time.
The accelerated proliferative effects of LR3IGF-I may have been the result of several interacting factors. LR3IGF-I has a severalfold lower affinity towards IGFBP-3, IGFBP-4, total rat plasma, and L6 myoblast binding proteins. ' single class ofhigh affinity IGF-I receptors have been localised to the muscular and mucosal layer of the gastrointestinal tract in rabbits25 and both type 1 and type 2 receptors are present in the porcine small intestine. 4 As shown by membrane receptor binding studies in the rat, 1251-IGF-I binding to IGF-I receptors was fourfold higher in proliferative crypt cells than in villus cells and IGF-I receptor densities are greater in the lamia propria than in the surface epithelium in adult rat intestine.23 This shows that the mitogenic properties of IGF-I peptides are more probably mediated by a direct interaction of the IGF-I ligand with the cell surface receptor. Indirect action of IGF peptides on gastrointestinal tissues can, however, not be dismissed and additional and synergistic interactions of IGF-I and other growth factors have been reported.'3 26 In agreement with previous studies,89 the proximal small intestine was identified as the most responsive region despite the fact that in the rat, binding of 1251-IGF-I is lower in cryostat sections of the proximal small intestine compared with the distal small intestine or the colon.20 23 In this study, administration of LR3IGF-I increased the wet tissue weight ofthe colon to a similar extent to that of the small intestine, yet an increase in thymidine labelling was not seen. The proliferative effect of IGF-I peptides may have been somewhat disguised by the inherent low proliferative activity of the colon. In the colon, variation in crypt morphology, in particular in the proximal colon, lead to a great deal of heterogeneity in morphometric and cell kinetic parameters. For example, in the rat, colonic crypts become longer and more slender with distance away from the ileocaecal junction. Furthermore, mucosal rugae are prominent in the proximal colon but not in the distal colon and crypts at the apex of the mucosal folds are longer than the crypts at the base of the folds (reviewed by Wright and Alison, ref 16 ). Thus, to estimate more accurately the proliferative response of IGF-I peptides on the colonic mucosa, direct measurements of cell cycle time or the crypt cell production rates, or both, need to be taken.
In summary, this study has shown that administration of LR3IGF-I for only three days strongly stimulated intestinal proliferation in normal adult rats. LR3IGF-I but not IGF-I increased the wet tissue weight of intestinal components independent of food intake. In this group, the crypt length and crypt cell number were increased in the duodenum and ileum. Although thymidine labelling indices were increased for both peptides, no change in the crypt length and crypt cell population was seen for IGF-I treated rats, suggesting that LR3IGF-I is not only more potent in stimulating intestinal proliferation but induces mitogenesis more rapidly.
